Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.

NCT05230810 is registered in ClinicalTrials.gov with Criterium, Inc. as lead sponsor.

NCT NCT05230810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05230810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.
Lead sponsor
Criterium, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 25, 2022
Completion date
June 30, 2026
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive metastatic breast cancer